Phase Ia study to evaluate GDC-6036 monotherapy in patients with colorectal cancer (CRC) with KRAS G12C mutation
Authors
Desai, J.Han, S. W.
Forster, M. D.
Kim, T. W.
Casal, G. A.
Shmueli, E. S.
Bowyer, S. E.
De Miguel, M. J.
Gonzalez, A. F.
Jones, R. H.
Krebs, Matthew G
Miller, W. H.
Paz-Ares, L.
Lorusso, P.
Sacher, A.
Dharia, N.
Lin, M. T.
Schutzman, J. L.
Shi, Z.
Patel, M.
Affiliation
Medical Oncology Department, Peter MacCallum Cancer Centre, Melbourne, VIC,AustraliaIssue Date
2022
Metadata
Show full item recordCitation
Desai J, Han SW, Forster MD, Kim TW, Casal GA, Shmueli ES, et al. Phase Ia study to evaluate GDC-6036 monotherapy in patients with colorectal cancer (CRC) with KRAS G12C mutation. Annals of Oncology. 2022 Sep;33(7):S701-S2. PubMed PMID: WOS:000866211600356.Journal
Annals of OncologyDOI
10.1016/annonc/annonc1048Additional Links
https://dx.doi.org/10.1016/annonc/annonc1048Type
Meetings and ProceedingsLanguage
enae974a485f413a2113503eed53cd6c53
10.1016/annonc/annonc1048